Abstract CT160: The integration of PD1 blockade with epigenetic therapy is highly active and safe in heavily treated patients with T-cell lymphomaEnrica Marchi, Owen A. O’Connor, Helen Ma et al.|Cancer Research|2020Cited by 4
Differences in critically ill-COVID-19 Patients in Tyrol during 2 Waves of a PandemicTimo Mayerhöfer, Michael Joannidis, Fabian Perschinka et al.|Unknown|2021Cited by 0